Against one of medicine's most stubborn adversaries — pancreatic cancer, where fewer than one in ten patients survive five years — researchers have identified a molecular candidate called DE19725241 that targets FTO, a protein woven into both tumor growth and immune response. The discovery emerged not from chance but from a methodical collaboration between artificial intelligence and laboratory science, sifting more than 22 million compounds down to a single lead worth pursuing. It is early, and the road to the clinic is long, but the work reflects how humanity is learning to search smarter in
Researchers identify promising FTO-targeting compound for pancreatic cancer
A systematic hunt through 22 million compounds narrowed to one.
Mark
So they found one compound out of 22 million. How do we know it's actually the right one?
Mimi
They used machine learning to rank candidates by how well they should bind to FTO, then validated the top pick computationally before testing it in cells. It's not random—there's a logic to the selection.
Luke
But "should bind" and "does bind" are different things. The computational models are predictions. The real test is the cell work.
Mark
And did it work in the cells?
Mimi
The source says they tested it in three pancreatic cancer lines and one normal line, but it doesn't report the actual results—whether it killed the cancer cells or how much damage it did to healthy tissue.
Luke
That's the crucial gap. We know they did the experiment. We don't know what they found.
Mark
So this is really just announcing that they've identified a candidate worth studying further?
Mimi
Exactly. It's a discovery paper, not a validation paper. They're saying, "Here's a compound that looks promising based on our screening and initial testing." The real work—proving it works and is safe—comes next.
Luke
And that "next" could take years. People reading this shouldn't think a treatment is around the corner.
Mark
Fair. But why does FTO matter in the first place?
Mimi
It's involved in how cells read and interpret RNA—the instructions for making proteins. Cancer cells often hijack these processes. If you can block FTO, you might be able to disrupt that hijacking.
Luke
That's the theory. Whether it actually works in a living organism is still unknown.
Le Pouls
- Pancreatic cancer's brutal survival rate — around 10 percent at five years — makes every credible new therapeutic lead a matter of genuine urgency.
- FTO, a protein entangled in both cancer progression and immune regulation, had long been a tantalizing target without a viable drug to match it.
- Researchers deployed AI-driven active learning to screen over 22 million molecular structures, collapsing what would have been years of lab work into a tractable search.
- DE19725241 survived rigorous computational stress-testing — molecular dynamics simulations, binding energy calculations — before being brought to actual cancer cell lines.
- The compound is now being evaluated against three pancreatic cancer cell lines alongside healthy tissue, the critical threshold that separates a promising molecule from a dangerous one.
- If it spares normal cells while suppressing tumor growth, DE19725241 could advance toward animal studies — the next rung on a long ladder toward human trials.
Against one of medicine's most stubborn adversaries — pancreatic cancer, where fewer than one in ten patients survive five years — researchers have identified a molecular candidate called DE19725241 that targets FTO, a protein woven into both tumor growth and immune response. The discovery emerged not from chance but from a methodical collaboration between artificial intelligence and laboratory science, sifting more than 22 million compounds down to a single lead worth pursuing. It is early, and the road to the clinic is long, but the work reflects how humanity is learning to search smarter in the face of overwhelming biological complexity.
A research team has identified a compound called DE19725241 as a potential new weapon against pancreatic cancer, targeting a protein known as FTO that sits at the crossroads of tumor progression and immune function. The work, published in BIO Integration, began with a biological puzzle: scientists understood that FTO mattered in cancer, but whether blocking it could help patients remained unproven.
To find out, the team first mined large genetic databases — TCGA and GTEx — to establish whether FTO activity correlated with patient outcomes across thousands of pancreatic cancer cases. Satisfied that the target made biological sense, they turned to an AI-assisted screening process, deploying machine learning algorithms to evaluate more than 22 million molecular candidates. From that vast library, DE19725241 emerged as the lead worth pursuing.
The compound then underwent a layered validation process: computational simulations modeled how it binds to FTO at the molecular level, while standard binding-strength calculations assessed its chemical fitness. The team subsequently moved to the laboratory bench, testing DE19725241 against three pancreatic cancer cell lines — and crucially, against a healthy pancreatic cell line to gauge whether it would harm normal tissue.
Those results will determine the compound's fate. Pancreatic cancer remains among the deadliest malignancies, with five-year survival rates hovering near 10 percent, lending weight to any credible new avenue of attack. Whether DE19725241 eventually reaches patients depends entirely on what the testing pipeline reveals next.
A team of researchers has identified a compound that may offer a new angle of attack against pancreatic cancer by targeting a protein called FTO, which sits at the intersection of tumor growth and immune function. The work, published in BIO Integration, emerged from a systematic hunt through more than 22 million potential drug candidates, narrowed down by artificial intelligence to a single lead compound: DE19725241.
The starting point was a puzzle. Scientists knew that FTO—the fat mass and obesity-associated protein—played a role in how cancers progress and how the immune system responds to them. But whether blocking FTO could actually help pancreatic cancer patients remained an open question. To find out, the research team first examined existing genetic databases, analyzing FTO expression patterns across thousands of pancreatic cancer cases and healthy tissue samples drawn from TCGA and GTEx datasets. This gave them a sense of whether FTO activity correlated with patient outcomes and whether targeting it made biological sense.
Then came the screening phase. Rather than testing compounds one by one in a lab—a process that would take years—the researchers used machine learning to sift through a library of more than 22 million molecular structures. Active learning algorithms identified the most promising candidates, dramatically shrinking the search space. From that vast pool, DE19725241 emerged as the lead compound worth pursuing further.
What followed was a cascade of computational and experimental validation. The team used binding pose metadynamics and molecular dynamics simulations to model how DE19725241 would actually interact with FTO at the molecular level, testing its behavior in multiple cellular environments. They ran MM/GBSA calculations—a standard method for predicting binding strength. Then they moved to the bench. The compound was tested against three different pancreatic cancer cell lines to see if it could slow or stop tumor cell growth. Critically, they also tested it on a normal pancreatic epithelial cell line to check whether it would harm healthy tissue.
The results of those cell-based experiments will determine whether DE19725241 advances to the next phase of development. If the compound shows promise in killing cancer cells while sparing normal ones, it could eventually move toward animal studies and, much further down the line, human trials. Pancreatic cancer remains one of the most lethal malignancies—five-year survival rates hover around 10 percent—so any new therapeutic avenue warrants serious attention. This work represents the kind of computational-experimental hybrid approach that has become standard in modern drug discovery: use AI to narrow the haystack, then validate the needle in the lab. Whether DE19725241 will ultimately reach patients depends on what happens next in the testing pipeline.
Envie de l'histoire complète ?
Lire l'original sur News-Medical.net ↗
Health & Medicine